Truscreen Director Nominations Closing Date

NZX/ASX Announcement

18 July 2022

TRUSCREEN DIRECTOR NOMINATIONS CLOSING DATE
TruScreen Group Limited (NZX/ASX: TRU) (TruScreen or the Company) advises that the 2022 Annual
Meeting (AM) of Shareholders of TruScreen will be held at 11am (NZ time) on Tuesday 6 September 2022.
The meeting will be held at Link Market Services Level 30 PWC Tower, 15 Customs Street West Auckland
and as an online event.
Details of how shareholders can access and participate in the AM will be released with the Notice of
Meeting which will be made available to all shareholders and released to NZX/ASX in the coming weeks.
An item of business at the AM will be the re-election and appointment of directors. The closing date for
director nominations is 5pm on Monday 1 August 2022.
Nominations may only be made by a shareholder entitled to attend and vote at the Annual Meeting which
will be held on 6 September 2022. The nomination must be accompanied by the consent, in writing, of
the person nominated and should contain a brief curriculum vitae of the nominee.
Nominations should be addressed to:
Guy Robertson
TruScreen Chief Financial Officer & Company Secretary
Email: guyrobertson@truscreen.com or info@truscreen.com

This announcement was approved for release by the Board.

-ENDS-

For more information, visit www.truscreen.com
or contact:

Juliet Hull
Chief Executive Officer
juliethull@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:
TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-
time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being
of women around the world.
TruScreen’s real-time cervical cancer technology utilises a digital wand which is placed on the surface of the
cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.
TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with
conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for
supporting laboratory infrastructure. As such, TruScreen’s target market is low and middle-income countries
where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico,
Africa, Russia and India. TruScreen’s cervical cancer screening device is CE-marked and certified for use
throughout Europe and NMPA (formerly CFDA) approved for sale in China. The global market potential for
TruScreen is significant.